(UL) Unilever - Overview
Exchange: NYSE •
Country: United Kingdom •
Currency: USD •
Type: Common Stock •
ISIN: US9047677045
Stock: Beauty, Personal Care, Home Care, Food
Total Rating 53
Risk 74
Buy Signal -0.53
| Risk 5d forecast | |
|---|---|
| Volatility | 18.1% |
| Relative Tail Risk | -7.81% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.05 |
| Alpha | -0.21 |
| Character TTM | |
|---|---|
| Beta | -0.078 |
| Beta Downside | 0.146 |
| Drawdowns 3y | |
|---|---|
| Max DD | 15.93% |
| CAGR/Max DD | 0.59 |
Description: UL Unilever March 05, 2026
Unilever PLC (UL) is a global fast-moving consumer goods company. It operates across multiple geographic regions and is structured into four main segments: Beauty & Wellbeing, Personal Care, Home Care, and Foods. The consumer staples sector, in which Unilever operates, is generally characterized by stable demand for essential products.
The Beauty & Wellbeing segment offers hair care, skincare, and prestige beauty products. Personal Care includes skin cleansing, deodorants, and oral care. Home Care provides fabric care and home hygiene products. The Foods segment covers cooking aids, condiments, and food solutions. This diversified product portfolio helps mitigate risks associated with reliance on a single product category.
Unilever markets its products under numerous well-known brands, including AXE, Dove, Hellmanns, and Knorr. The company, founded in 1860 and headquartered in London, UK, is a long-standing player in the consumer goods industry. To understand the companys financial performance in more detail, consider reviewing its comprehensive data on ValueRay.
Headlines to watch out for
- Commodity price volatility impacts input costs
- Emerging market growth drives personal care sales
- Regulatory scrutiny on environmental claims increases
- Consumer preference shifts affect food segment revenue
- Exchange rate fluctuations influence reported earnings
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income: 11.82b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.21 > 0.02 and ΔFCF/TA 5.18 > 1.0 |
| NWC/Revenue: -4.13% < 20% (prev -6.27%; Δ 2.14% < -1%) |
| CFO/TA 0.26 > 3% & CFO 18.04b > Net Income 11.82b |
| Net Debt (25.65b) to EBITDA (24.12b): 1.06 < 3 |
| Current Ratio: 0.79 > 1.5 & < 3 |
| Outstanding Shares: last quarter (2.20b) vs 12m ago -13.16% < -2% |
| Gross Margin: 69.99% > 18% (prev 0.25%; Δ 6974 % > 0.5%) |
| Asset Turnover: 152.8% > 50% (prev 118.9%; Δ 33.91% > 0%) |
| Interest Coverage Ratio: 14.01 > 6 (EBITDA TTM 24.12b / Interest Expense TTM 1.50b) |
Altman Z'' 2.98
| A: -0.07 (Total Current Assets 17.06b - Total Current Liabilities 21.65b) / Total Assets 70.44b |
| B: 0.63 (Retained Earnings 44.21b / Total Assets 70.44b) |
| C: 0.29 (EBIT TTM 21.06b / Avg Total Assets 72.83b) |
| D: -0.55 (Book Value of Equity -29.04b / Total Liabilities 52.86b) |
| Altman-Z'' Score: 2.98 = A |
Beneish M -3.32
| DSRI: 1.25 (Receivables 7.67b/4.94b, Revenue 111.26b/89.41b) |
| GMI: 0.35 (GM 69.99% / 24.55%) |
| AQI: 1.02 (AQ_t 0.63 / AQ_t-1 0.62) |
| SGI: 1.24 (Revenue 111.26b / 89.41b) |
| TATA: -0.09 (NI 11.82b - CFO 18.04b) / TA 70.44b) |
| Beneish M-Score: -3.32 (Cap -4..+1) = AA |
What is the price of UL shares?
As of March 11, 2026, the stock is trading at USD 66.38 with a total of 3,228,291 shares traded.
Over the past week, the price has changed by -4.01%, over one month by -7.06%, over three months by +4.74% and over the past year by +0.93%.
Over the past week, the price has changed by -4.01%, over one month by -7.06%, over three months by +4.74% and over the past year by +0.93%.
Is UL a buy, sell or hold?
Unilever has received a consensus analysts rating of 4.00.
Therefore, it is recommended to buy UL.
- StrongBuy: 2
- Buy: 0
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the UL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 74.6 | 12.4% |
| Analysts Target Price | 74.6 | 12.4% |
UL Fundamental Data Overview March 10, 2026
P/E Trailing = 22.1993
P/E Forward = 18.0832
P/S = 2.893
P/B = 8.0804
P/EG = 2.0539
Revenue TTM = 111.26b USD
EBIT TTM = 21.06b USD
EBITDA TTM = 24.12b USD
Long Term Debt = 25.70b USD (from longTermDebt, last quarter)
Short Term Debt = 2.58b USD (from shortTermDebt, last quarter)
Debt = 29.59b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 25.65b USD (from netDebt column, last quarter)
Enterprise Value = 171.76b USD (146.11b + Debt 29.59b - CCE 3.94b)
Interest Coverage Ratio = 14.01 (Ebit TTM 21.06b / Interest Expense TTM 1.50b)
EV/FCF = 11.57x (Enterprise Value 171.76b / FCF TTM 14.84b)
FCF Yield = 8.64% (FCF TTM 14.84b / Enterprise Value 171.76b)
FCF Margin = 13.34% (FCF TTM 14.84b / Revenue TTM 111.26b)
Net Margin = 10.62% (Net Income TTM 11.82b / Revenue TTM 111.26b)
Gross Margin = 69.99% ((Revenue TTM 111.26b - Cost of Revenue TTM 33.39b) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 2.44 (Enterprise Value 171.76b / Total Assets 70.44b)
Interest Expense / Debt = 1.57% (Interest Expense 464.5m / Debt 29.59b)
Taxrate = 33.81% (1.10b / 3.26b)
NOPAT = 13.94b (EBIT 21.06b * (1 - 33.81%))
Current Ratio = 0.79 (Total Current Assets 17.06b / Total Current Liabilities 21.65b)
Debt / Equity = 1.91 (Debt 29.59b / totalStockholderEquity, last quarter 15.52b)
Debt / EBITDA = 1.06 (Net Debt 25.65b / EBITDA 24.12b)
Debt / FCF = 1.73 (Net Debt 25.65b / FCF TTM 14.84b)
Total Stockholder Equity = 18.40b (last 4 quarters mean from totalStockholderEquity)
RoA = 16.23% (Net Income 11.82b / Total Assets 70.44b)
RoE = 64.23% (Net Income TTM 11.82b / Total Stockholder Equity 18.40b)
RoCE = 47.76% (EBIT 21.06b / Capital Employed (Equity 18.40b + L.T.Debt 25.70b))
RoIC = 47.93% (NOPAT 13.94b / Invested Capital 29.09b)
WACC = 4.86% (E(146.11b)/V(175.70b) * Re(5.63%) + D(29.59b)/V(175.70b) * Rd(1.57%) * (1-Tc(0.34)))
Discount Rate = 5.63% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -6.81%
[DCF] Terminal Value 88.43% ; FCFF base≈13.69b ; Y1≈16.89b ; Y5≈28.76b
[DCF] Fair Price = 371.5 (EV 837.42b - Net Debt 25.65b = Equity 811.77b / Shares 2.18b; r=5.90% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: -11.90 | EPS CAGR: -61.30% | SUE: 0.0 | # QB: 0
Revenue Correlation: 6.50 | Revenue CAGR: -7.55% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=3.16 | Chg7d=-0.029 | Chg30d=+0.089 | Revisions Net=+0 | Growth EPS=+2.5% | Growth Revenue=+1.7%
EPS next Year (2027-12-31): EPS=3.36 | Chg7d=-0.048 | Chg30d=-0.111 | Revisions Net=-1 | Growth EPS=+6.4% | Growth Revenue=+3.7%
[Analyst] Revisions Ratio: +0.00 (1 Up / 1 Down within 30d for Current Year)
[Growth] Implied Growth Rate = 3.4% (Discount Rate 7.9% - Earnings Yield 4.5%)
[Growth] Growth Spread = +0.3% (Analyst 3.7% - Implied 3.4%)
P/E Forward = 18.0832
P/S = 2.893
P/B = 8.0804
P/EG = 2.0539
Revenue TTM = 111.26b USD
EBIT TTM = 21.06b USD
EBITDA TTM = 24.12b USD
Long Term Debt = 25.70b USD (from longTermDebt, last quarter)
Short Term Debt = 2.58b USD (from shortTermDebt, last quarter)
Debt = 29.59b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 25.65b USD (from netDebt column, last quarter)
Enterprise Value = 171.76b USD (146.11b + Debt 29.59b - CCE 3.94b)
Interest Coverage Ratio = 14.01 (Ebit TTM 21.06b / Interest Expense TTM 1.50b)
EV/FCF = 11.57x (Enterprise Value 171.76b / FCF TTM 14.84b)
FCF Yield = 8.64% (FCF TTM 14.84b / Enterprise Value 171.76b)
FCF Margin = 13.34% (FCF TTM 14.84b / Revenue TTM 111.26b)
Net Margin = 10.62% (Net Income TTM 11.82b / Revenue TTM 111.26b)
Gross Margin = 69.99% ((Revenue TTM 111.26b - Cost of Revenue TTM 33.39b) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 2.44 (Enterprise Value 171.76b / Total Assets 70.44b)
Interest Expense / Debt = 1.57% (Interest Expense 464.5m / Debt 29.59b)
Taxrate = 33.81% (1.10b / 3.26b)
NOPAT = 13.94b (EBIT 21.06b * (1 - 33.81%))
Current Ratio = 0.79 (Total Current Assets 17.06b / Total Current Liabilities 21.65b)
Debt / Equity = 1.91 (Debt 29.59b / totalStockholderEquity, last quarter 15.52b)
Debt / EBITDA = 1.06 (Net Debt 25.65b / EBITDA 24.12b)
Debt / FCF = 1.73 (Net Debt 25.65b / FCF TTM 14.84b)
Total Stockholder Equity = 18.40b (last 4 quarters mean from totalStockholderEquity)
RoA = 16.23% (Net Income 11.82b / Total Assets 70.44b)
RoE = 64.23% (Net Income TTM 11.82b / Total Stockholder Equity 18.40b)
RoCE = 47.76% (EBIT 21.06b / Capital Employed (Equity 18.40b + L.T.Debt 25.70b))
RoIC = 47.93% (NOPAT 13.94b / Invested Capital 29.09b)
WACC = 4.86% (E(146.11b)/V(175.70b) * Re(5.63%) + D(29.59b)/V(175.70b) * Rd(1.57%) * (1-Tc(0.34)))
Discount Rate = 5.63% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -6.81%
[DCF] Terminal Value 88.43% ; FCFF base≈13.69b ; Y1≈16.89b ; Y5≈28.76b
[DCF] Fair Price = 371.5 (EV 837.42b - Net Debt 25.65b = Equity 811.77b / Shares 2.18b; r=5.90% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: -11.90 | EPS CAGR: -61.30% | SUE: 0.0 | # QB: 0
Revenue Correlation: 6.50 | Revenue CAGR: -7.55% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=3.16 | Chg7d=-0.029 | Chg30d=+0.089 | Revisions Net=+0 | Growth EPS=+2.5% | Growth Revenue=+1.7%
EPS next Year (2027-12-31): EPS=3.36 | Chg7d=-0.048 | Chg30d=-0.111 | Revisions Net=-1 | Growth EPS=+6.4% | Growth Revenue=+3.7%
[Analyst] Revisions Ratio: +0.00 (1 Up / 1 Down within 30d for Current Year)
[Growth] Implied Growth Rate = 3.4% (Discount Rate 7.9% - Earnings Yield 4.5%)
[Growth] Growth Spread = +0.3% (Analyst 3.7% - Implied 3.4%)